Has Gary Gross received payments from drug or device companies?

Yes. Drug and device makers reported $3,717,105 in general payments to Gary Gross across 1,582 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gary Gross did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gary Gross come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gary Gross

Allergy · Dallas, TXNPI 1285601336

Payments from drug & device makers

$3,717,105in general payments, 2019–2025

Across 1,582 payments — averaging $2349.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1.1M
GSK$550K
Teva Pharmaceuticals USA, Inc.$353K
Novartis$262K
Sanofi US Services Inc.$250K
Genentech, Inc.$228K
plus $976K from 42 others

$5,537in research payments, 2019–2025

Across 19 payments — averaging $291.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi$2K
Sanofi-aventis U.S. LLC$2K
Sanofi US Services Inc.$1K
Insmed, Inc.$960

What the payments were for

Consulting fees$60,24510%
Speaking & faculty fees$451,39375%
Travel & lodging$65,00611%
Food & beverage$25,3894%
Education$1850%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	263	$1,099,052
GSK	100	$549,573
Teva Pharmaceuticals USA, Inc.	117	$352,600
Novartis	53	$262,203
Sanofi US Services Inc.	82	$249,634
Genentech, Inc.	37	$228,043
Sanofi	237	$200,481
Hikma Pharmaceuticals USA	23	$186,619
Regeneron Healthcare Solutions, Inc.	285	$172,535
Bayer	16	$104,274
Astrazeneca UK Limited	3	$86,720
Shionogi Inc	25	$73,098
Merck	52	$70,197
Insmed, Inc.	8	$30,607
Optinose US, Inc.	55	$27,684
Alk-abello, Inc	31	$8,462
Chiesi USA, Inc.	1	$4,000
Pfizer	4	$2,654
Regeneron	1	$2,425
Glenmark Therapeutics Inc.	1	$1,017
Sanofi-aventis U.S. LLC	9	$616
Blueprint Medicines Corporation	8	$608
Covis Pharma GmbH	34	$564
Grifols USA, LLC	21	$539
CSL Behring	14	$392
Takeda Pharmaceuticals U.S.A., Inc.	17	$367
Genentech USA, Inc.	12	$300
Kaleo, Inc.	12	$267
Pharming Healthcare, Inc.	8	$260
ARS Pharmaceuticals Operations, Inc.	10	$257
Octapharma USA, Inc.	4	$162
Boehringer Ingelheim	6	$133
Aquestive Therapeutics, Inc.	1	$119
Incyte Corporation	5	$101
LEO Pharma Inc.	3	$80
Biocryst US Sales Co., LLC	4	$77
Hospira, Inc.	4	$71
AbbVie	3	$60
Biocryst Pharmaceuticals, Inc.	2	$46
Shire North American Group Inc	2	$37
Siemens Medical Solutions USA, Inc.	1	$36
Ionis Pharmaceuticals, Inc.	1	$26
Organon	2	$24
Azurity Pharmaceuticals, Inc.	1	$22
Lilly USA, LLC	1	$19
Amgen	1	$16
USWM, LLC	1	$15
Almirall LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$366,093
AIRSUPRA$105,379
Xhance$26,751
ArmonAir Digihaler$14,856
AirDuo RespiClick$14,856
ProAir Digihaler$14,856
Ryaltris$14,173
Odactra$7,947
XOLAIR$7,359
FASENRA$5,308
Ragwitek$4,428
Grastek$4,428
Rhapsido$823
AYVAKIT$504
GILENYA$444
Xembify$156
JOENJA$122
LIBERVANT$119
Haegarda$106
TEZSPIRE$101

How this compares

$3,717,105 in reported general payments places this provider in the 95th percentile of 69 allergy providers in Texas.

See all allergy providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Montelukast Sodium	11	$124

Paid to pharmacies, not to this prescriber.

Other allergy in Dallas

Christina HuddlestonDallas$26K
Sandeep GuptaDallas$10K
Erin ClarkeDallas$8K
Michael RuffDallas$5K
Steven ColeDallas$5K
Tran LyDallas$4K
David FuentesBoerne$14.5M
Swapnil VaidyaFort Worth$484K
John FlingFort Worth$193K
Brian MillerGeorgetown$168K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →